ArticleThe Journal of clinical investigation2021

Inhibition of relaxin autocrine signaling confers therapeutic vulnerability in ovarian cancer.

Helen E Burston et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.